The Relation of Initial Methimazole Dose to the Incidence of Methimazole-induced Agranulocytosis in Patients with Graves' Disease

Endocrine Journal

Hajime UESHIBA¹  Rena YUASA¹  Kaoru NAGASAWA¹  Kumiko TSUBOI¹  Mayumi ISHIKAWA¹  Gen YOSHINO¹  Masako SHIMOJO¹  Natsuko WATANABE¹ 

[1] of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University School of Medicine

关键词: Antithyroid-drug;    ATD;    Agranulocytosis;    Graves' disease;    MMI;    Methimazole;    Methylmercaptoimidazole;   

DOI  :  10.1507/endocrj.K05-068

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(16)Cited-By(10)The relation between the incidence of methimazole (methylmercaptoimidazole; MMI)-induced agranulocytosis and initial MMI dose was evaluated in a group of 514 patients with Graves' disease who were treated between 1995 and 2005. One hundred and forty-six (28.40%) patients had received an initial dose of 30 mg MMI and 277 (53.89%) patients had been treated with 15 mg MMI. Nine patients (1.75%) developed agranulocytosis due to MMI treatment. Six (4.11%) of 146 patients who received an initial dose of 30 mg MMI, two (4.54%) of 44 patients given an initial dose of 20 mg MMI, and one (0.36%) of 277 patients given an initial dose of 15 mg MMI developed agranulocytosis. There was a statistically significant difference in agranulocytosis incidence between patients receiving an initial dose of 30 mg MMI and those who received an initial dose of 15 mg. Although 8 (4.10%) of 195 patients in the high-dose group (20 mg or higher) developed agranulocytosis, only 1 (0.31%) of 319 patients in the low-dose group (15 mg or lower) did. In conclusion, the incidence of agranulocytosis with low-dose MMI therapy was ten times lower than that of the high-dose regimen.

【 授权许可】

Unknown